Aligos Therapeutics (NASDAQ:ALGS) Stock Price Up 4.9% – Still a Buy?

Aligos Therapeutics, Inc. (NASDAQ:ALGS)’s stock price rose 4.9% during mid-day trading on Wednesday . The stock traded as high as $7.84 and last traded at $7.68. Approximately 19,208 shares traded hands during mid-day trading, a decline of 35% from the average daily volume of 29,566 shares. The stock had previously closed at $7.32.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reissued a “buy” rating and set a $75.00 price objective on shares of Aligos Therapeutics in a research report on Friday, September 20th.

Aligos Therapeutics Trading Up 6.0 %

The business’s fifty day simple moving average is $11.97 and its two-hundred day simple moving average is $14.95. The stock has a market capitalization of $606.13 million, a P/E ratio of -6.00 and a beta of 2.16.

Aligos Therapeutics (NASDAQ:ALGS) last released its quarterly earnings data on Tuesday, August 6th. The company reported $0.75 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($4.00) by $4.75. The business had revenue of $1.06 million for the quarter. Aligos Therapeutics had a negative return on equity of 110.59% and a negative net margin of 1,100.48%. During the same quarter in the prior year, the firm posted ($10.75) earnings per share. On average, equities research analysts anticipate that Aligos Therapeutics, Inc. will post -8.2 earnings per share for the current year.

Institutional Investors Weigh In On Aligos Therapeutics

Several large investors have recently made changes to their positions in the company. Acadian Asset Management LLC increased its holdings in shares of Aligos Therapeutics by 26.1% in the second quarter. Acadian Asset Management LLC now owns 829,485 shares of the company’s stock valued at $289,000 after purchasing an additional 171,490 shares in the last quarter. Opaleye Management Inc. acquired a new position in shares of Aligos Therapeutics during the fourth quarter valued at $861,000. Altitude Crest Partners Inc. bought a new position in Aligos Therapeutics in the fourth quarter valued at about $1,889,000. Finally, Armistice Capital LLC increased its position in Aligos Therapeutics by 5.3% in the second quarter. Armistice Capital LLC now owns 7,256,410 shares of the company’s stock worth $2,540,000 after purchasing an additional 363,000 shares during the period. Institutional investors own 60.43% of the company’s stock.

Aligos Therapeutics Company Profile

Aligos Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH).